NASDAQ: DMKDmk Pharmaceuticals Corp Stock
$0.60+0.01 (+1.69%)
Updated Dec 8, 2023
DMK Price
$0.60
Fair Value Price
N/A
Market Cap
$6.06M
52 Week Low
$0.45
52 Week High
$21.70
P/E
-0.06x
P/B
-1.14x
P/S
1.35x
PEG
N/A
Dividend Yield
N/A
Revenue
$3.62M
Earnings
-$22.23M
Gross Margin
-37.3%
Operating Margin
-623.76%
Profit Margin
-614.2%
Debt to Equity
-2.63
Operating Cash Flow
-$9M
Beta
0.74
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
DMK Overview
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease in the United States. The company's product candidates comprise SYMJEPI epinephrine pre-filled syringe injectable products for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products for the treatment of asthma; and naloxone injection for the treatment of opioid overdose. It also offers APC400, a tempol gel use of reducing radiation dermatitis in patients undergoing treatment for cancer; and APC410 for the treatment of respiratory diseases, including asthma, respiratory syncytial virus, influenza, and COVID-19. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, and injectables; and veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation was founded in 2006 and is headquartered in San Diego, California.
Zen Score
–
Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how DMK scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
DMK is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
DMK is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
DMK's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more DMK due diligence checks available for Premium users.
Be the first to know about important DMK news, forecast changes, insider trades & much more!
DMK News
Valuation
DMK price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.06x
Industry
9.46x
Market
31.32x
DMK price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-1.14x
Industry
2.05x
DMK's financial health
Profit margin
Revenue
$9.1k
Net Income
-$1.4M
Profit Margin
-15,317.2%
DMK's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
DMK's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$9.0M
Liabilities
$13.9M
Debt to equity
-2.63
DMK's short-term liabilities ($13.46M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
DMK's short-term assets ($7.87M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
DMK's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
DMK's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.7M
Investing
$1.8M
Financing
$8.0M
DMK's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
DMK vs Pharmaceutical Stocks
Dmk Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.